HansBiomed Corporation (KOSDAQ:042520)
South Korea flag South Korea · Delayed Price · Currency is KRW
19,100
-600 (-3.05%)
At close: Jul 27, 2026

HansBiomed Financials Overview

Millions KRW. Fiscal year is Oct - Sep.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Revenue
110,50089,78081,13778,03274,45959,098
Revenue Growth
30.99%10.65%3.98%4.80%25.99%-26.22%
Gross Profit
65,37051,51451,74745,12345,68329,229
Operating Income
-22,407-27,891625.6-4,1551,256-19,778
Net Income
-24,848-31,341-7,223-23,0456,147-18,289
Earnings Per Share
-1854.43-2413.29-558.00-2150.23180.37-1827.00
EPS Growth
------

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Human Tissue Section
104,41873,78351,98548,98043,37334,029
Medical Device Division
46,44246,92155,49554,83454,58643,791
Other Section
7,3417,7576,2635,2074,3234,230
Unallocated Adjustment
-47,701-38,681-32,605-30,989-27,824-22,952
Total
110,50089,78081,13778,03274,45959,098

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Cash & Investments
17,9548,1497,2597,04813,55320,268
Total Debt
42,22643,30736,43041,14155,91051,577
Net Cash (Debt)
-24,272-35,158-29,171-34,093-42,356-31,309
Net Cash Growth
------
Net Cash Per Share
-1811.05-2707.17-2252.56-3181.12-3224.39-3127.17

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Operating Cash Flow
-20,211318.341,759-3,733-4,270-14,645
Capital Expenditures
-2,449-1,862-2,594-1,937-3,986-4,891
Free Cash Flow
-22,660-1,544-835.74-5,670-8,256-19,535
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
Gross Margin
59.16%57.38%63.78%57.83%61.35%49.46%
Operating Margin
-20.28%-31.06%0.77%-5.33%1.69%-33.47%
Pretax Margin
-21.17%-33.14%-8.17%-30.16%4.70%-36.58%
Profit Margin
-22.49%-34.91%-8.90%-29.53%8.26%-30.95%
FCF Margin
-20.51%-1.72%-1.03%-7.27%-11.09%-33.06%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21
PE Ratio
----15.12-
Forward PE
12.7213.8713.8713.876.956.95
PS Ratio
2.412.631.582.661.252.72